

William M Gallagher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4458183/publications.pdf>

Version: 2024-02-01

231
papers

17,511
citations

18482

62
h-index

15732

125
g-index

240
all docs

240
docs citations

240
times ranked

29395
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>PRR11</scp> unveiled as a top candidate biomarker within the <scp>RBM3</scp>â€regulated transcriptome in pancreatic cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 65-77.	3.0	5
2	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	2.5	26
3	Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity. <i>BMC Cancer</i> , 2022, 22, 131.	2.6	3
4	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2022, , .	3.2	5
5	Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 155-169.	3.4	8
6	Plant-derived cannabinoids as anticancer agents. <i>Trends in Cancer</i> , 2022, 8, 350-357.	7.4	7
7	Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cellâ€Cell Interactions That Predict Immunotherapy Response. <i>Cancer Research</i> , 2022, 82, 3275-3290.	0.9	17
8	Effects of HER Familyâ€targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 807-818.	7.0	34
9	Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection. <i>Analyst, The</i> , 2021, 146, 4195-4211.	3.5	11
10	The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development. <i>Frontiers in Oncology</i> , 2021, 11, 626349.	2.8	54
11	Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. <i>Journal of Clinical Pathology</i> , 2021, 74, 429-434.	2.0	19
12	Prognostic value of the 6-gene OncoMasTR test in hormone receptorâ€positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. <i>European Journal of Cancer</i> , 2021, 152, 78-89.	2.8	2
13	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptorâ€Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. <i>Clinical Cancer Research</i> , 2021, 27, 5931-5938.	7.0	1
14	Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. <i>Clinical Epigenetics</i> , 2021, 13, 168.	4.1	14
15	ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling. <i>Oncogene</i> , 2021, 40, 6235-6247.	5.9	16
16	Association of circulating short chain fatty acid levels with colorectal adenomas and colorectal cancer. <i>Clinical Nutrition ESPEN</i> , 2021, 46, 297-304.	1.2	10
17	Validation of the OncoMasTR Risk Score in Estrogen Receptorâ€Positive/HER2-Negative Patients: A TransATAC study. <i>Clinical Cancer Research</i> , 2020, 26, 623-631.	7.0	10
18	A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of ERÎ± in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 5076-5088.	0.9	18

#	ARTICLE	IF	CITATIONS
19	Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 2978.	3.7	8
20	Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer. <i>Cancers</i> , 2020, 12, 3540.	3.7	4
21	Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland. <i>Cancers</i> , 2020, 12, 1921.	3.7	4
22	The Molecular Effects of a High Fat Diet on Endometrial Tumour Biology. <i>Life</i> , 2020, 10, 188.	2.4	4
23	High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. <i>Cancers</i> , 2020, 12, 2950.	3.7	19
24	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42.	1.2	15
25	Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 1133.	3.7	14
26	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. <i>Cancer Research</i> , 2020, 80, 2983-2995.	0.9	51
27	Advances in tissue-based imaging: impact on oncology research and clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 1027-1037.	3.1	5
28	An EPR Strategy for Bio-responsive Fluorescence Guided Surgery with Simulation of the Benefit for Imaging. <i>Theranostics</i> , 2020, 10, 3064-3082.	10.0	11
29	Clinical Decision Support Systems in Breast Cancer: A Systematic Review. <i>Cancers</i> , 2020, 12, 369.	3.7	50
30	Evaluating liquid biopsies for methylomic profiling of prostate cancer. <i>Epigenetics</i> , 2020, 15, 715-727.	2.7	13
31	Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells. <i>Antioxidants</i> , 2020, 9, 320.	5.1	18
32	Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08's10 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986423.	3.2	10
33	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7139-7150.	7.0	18
34	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	7.0	17
35	Colitis susceptibility in mice with reactive oxygen species deficiency is mediated by mucus barrier and immune defense defects. <i>Mucosal Immunology</i> , 2019, 12, 1316-1326.	6.0	44
36	RGD conjugated cell uptake off to on responsive NIR-AZA fluorophores: applications toward intraoperative fluorescence guided surgery. <i>Chemical Science</i> , 2019, 10, 6944-6956.	7.4	33

#	ARTICLE	IF	CITATIONS
37	PDLIM2 Is a Marker of Adhesion and β -Catenin Activity in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 2619-2633.	0.9	14
38	Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes. <i>Circulation: Heart Failure</i> , 2019, 12, e005765.	3.9	58
39	Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-clinical Detection of Off-target Toxicities Associated with Sunitinib Malate. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800159.	1.6	3
40	PEGylated BF2-Azadipyromethene (NIR-AZA) fluorophores, for intraoperative imaging. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 343-353.	5.5	19
41	Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland.. <i>Journal of Clinical Oncology</i> , 2019, 37, 535-535.	1.6	2
42	1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours. <i>Oncotarget</i> , 2019, 10, 3725-3744.	1.8	5
43	Role of serum response factor expression in prostate cancer biochemical recurrence. <i>Prostate</i> , 2018, 78, 724-730.	2.3	8
44	Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. <i>Oncogene</i> , 2018, 37, 2137-2149.	5.9	150
45	Epigenetics of malignant melanoma. <i>Seminars in Cancer Biology</i> , 2018, 51, 80-88.	9.6	95
46	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. <i>Cancer Letters</i> , 2018, 414, 99-106.	7.2	48
47	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. <i>BMC Cancer</i> , 2018, 18, 965.	2.6	21
48	Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers. <i>Journal of Molecular Medicine</i> , 2018, 96, 1025-1037.	3.9	9
49	Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877829.	3.2	11
50	Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. <i>Oncotarget</i> , 2018, 9, 6188-6200.	1.8	13
51	BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer. <i>Oncotarget</i> , 2018, 9, 15673-15690.	1.8	22
52	Vitamin D receptor as a target for breast cancer therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, 181-195.	3.1	40
53	The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. <i>Journal of Biological Chemistry</i> , 2017, 292, 3543-3551.	3.4	41
54	Master Transcriptional Regulators in Cancer: Discovery via Reverse Engineering Approaches and Subsequent Validation. <i>Cancer Research</i> , 2017, 77, 2186-2190.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3834-3845.	0.9	79
56	Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma. <i>BMC Medicine</i> , 2017, 15, 101.	5.5	62
57	Circulating MicroRNAs in Cancer. <i>Methods in Molecular Biology</i> , 2017, 1509, 123-139.	0.9	18
58	Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology. <i>Methods in Molecular Biology</i> , 2017, 1501, 311-325.	0.9	4
59	Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?. <i>International Journal of Cancer</i> , 2017, 140, 234-246.	5.1	79
60	Postmortem Examination of an Aggressive Case of Medullary Thyroid Carcinoma Characterized by Catastrophic Genomic Abnormalities. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	3.0	1
61	Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. <i>Breast Cancer Research</i> , 2017, 19, 87.	5.0	29
62	A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate. <i>PLoS ONE</i> , 2017, 12, e0169964.	2.5	26
63	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 42949-42961.	1.8	42
64	Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach. <i>Oncotarget</i> , 2017, 8, 48126-48137.	1.8	12
65	Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 103.	3.7	41
66	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. <i>Scientific Reports</i> , 2016, 6, 18517.	3.3	143
67	Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. <i>Scientific Reports</i> , 2016, 6, 34523.	3.3	17
68	De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage III breast cancer. <i>British Journal of Cancer</i> , 2016, 115, 592-598.	6.4	16
69	RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw111.	6.3	11
70	Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time. <i>Nature Communications</i> , 2016, 7, 10855.	12.8	164
71	Functionalization of emissive conjugated polymer nanoparticles by coprecipitation: consequences for particle photophysics and colloidal properties. <i>Nanotechnology</i> , 2016, 27, 305603.	2.6	11
72	Prognostic and predictive biomarkers in melanoma: an update. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 223-237.	3.1	23

#	ARTICLE	IF	CITATIONS
73	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. Expert Review of Molecular Diagnostics, 2016, 16, 541-551.	3.1	4
74	The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer. Oncotarget, 2016, 7, 75518-75525.	1.8	12
75	Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients. FEBS Journal, 2015, 282, 3455-3473.	4.7	12
76	Relationship between serum response factor and androgen receptor in prostate cancer. Prostate, 2015, 75, 1704-1717.	2.3	7
77	High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Research, 2015, 25, 189-199.	1.2	13
78	Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. PLoS ONE, 2015, 10, e0133449.	2.5	23
79	miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget, 2015, 6, 32774-32789.	1.8	203
80	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nature Medicine, 2015, 21, 741-750.	30.7	107
81	The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides. Journal of Biotechnology, 2015, 204, 7-12.	3.8	15
82	Commercialized biomarkers: new horizons in prostate cancer diagnostics. Expert Review of Molecular Diagnostics, 2015, 15, 491-503.	3.1	13
83	Epidemiologic Design and Analysis for Proteomic Studies: A Primer on -Omic Technologies. American Journal of Epidemiology, 2015, 181, 635-647.	3.4	30
84	Tumour islet Foxp3 ⁺ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. European Respiratory Journal, 2015, 46, 1762-1772.	6.7	56
85	The Role of Exosomes in Breast Cancer. Clinical Chemistry, 2015, 61, 1457-1465.	3.2	105
86	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	1.8	13
87	Fibulins. , 2015, , 1-5.		0
88	Fibulins. , 2015, , 1725-1729.		0
89	The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases. Prostate, 2014, 74, 306-313.	2.3	14
90	A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. Breast Cancer Research, 2014, 16, 467.	5.0	11

#	ARTICLE	IF	CITATIONS
91	OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. <i>Molecular Cancer</i> , 2014, 13, 241.	19.2	27
92	Peroxiredoxin-1 protects estrogen receptor β from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R79.	5.0	52
93	Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers. <i>Molecular Oncology</i> , 2014, 8, 783-798.	4.6	122
94	Investigation of molecular alterations of β -catenin in triple-negative breast cancer. <i>Histopathology</i> , 2014, 64, 660-670.	2.9	20
95	p53 as a target for the treatment of cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 1153-1160.	7.7	187
96	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. <i>Cell Death and Differentiation</i> , 2014, 21, 1250-1261.	11.2	195
97	microRNAs: a new class of breast cancer biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 347-363.	3.1	36
98	Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. <i>BMC Cancer</i> , 2013, 13, 175.	2.6	64
99	The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate. <i>Biomaterials</i> , 2013, 34, 2710-2718.	11.4	55
100	miRNA Dysregulation in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6554-6562.	0.9	217
101	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
102	BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome. <i>Breast Cancer Research</i> , 2013, 15, R52.	5.0	124
103	Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. <i>Cancer Research</i> , 2013, 73, 1128-1141.	0.9	797
104	Identification of transcription factors associated with castration-resistance: Is the serum responsive factor a potential therapeutic target?. <i>Prostate</i> , 2013, 73, 743-753.	2.3	18
105	MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. <i>BMC Bioinformatics</i> , 2013, 14, 338.	2.6	84
106	Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. <i>Carcinogenesis</i> , 2013, 34, 2300-2308.	2.8	359
107	A Texture Based Pattern Recognition Approach to Distinguish Melanoma from Non-Melanoma Cells in Histopathological Tissue Microarray Sections. <i>PLoS ONE</i> , 2013, 8, e62070.	2.5	20
108	Development of a Pharmaceutical Hepatotoxicity Biomarker Panel Using a Discovery to Targeted Proteomics Approach. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 394-410.	3.8	32

#	ARTICLE	IF	CITATIONS
109	Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers. <i>Cancer Research</i> , 2012, 72, 2428-2439.	0.9	124
110	A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2012, 72, 66-75.	0.9	189
111	miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential <i>in Vitro</i> . <i>Clinical Cancer Research</i> , 2012, 18, 6702-6713.	7.0	75
112	The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER α , and is an independent prognostic factor in node-negative breast cancer. <i>Oncogene</i> , 2012, 31, 3483-3494.	5.9	10
113	Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. <i>Expert Review of Proteomics</i> , 2012, 9, 415-423.	3.0	9
114	Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. <i>BMC Cancer</i> , 2012, 12, 209.	2.6	7
115	Focus on Cancer Proteomics 12'13. <i>Proteomics</i> , 2012, 12, 2065-2066.	2.2	1
116	Mechanism of cell death mediated by a BF ₂ -chelated tetraarylzadipyromethene photodynamic therapeutic: Dissection of the apoptotic pathway <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2012, 130, 705-715.	5.1	36
117	Sequence Tagging Reveals Unexpected Modifications in Toxicoproteomics. <i>Chemical Research in Toxicology</i> , 2011, 24, 204-216.	3.3	25
118	Fibulins and Their Role in the ECM. , 2011, , 159-174.		0
119	P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. <i>Nature Communications</i> , 2011, 2, 555.	12.8	152
120	Functionalized Scaffold-mediated Interleukin 10 Gene Delivery Significantly Improves Survival Rates of Stem Cells <i>In Vivo</i> . <i>Molecular Therapy</i> , 2011, 19, 969-978.	8.2	38
121	Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. <i>Breast Cancer Research</i> , 2011, 13, R12.	5.0	22
122	Effect of Surface Wettability and Topography on the Adhesion of Osteosarcoma Cells on Plasma-modified Polystyrene. <i>Journal of Biomaterials Applications</i> , 2011, 26, 327-347.	2.4	314
123	Serum Proteomic Profiling Reveals That Pretreatment Complement Protein Levels are Predictive of Esophageal Cancer Patient Response to Neoadjuvant Chemoradiation. <i>Annals of Surgery</i> , 2011, 254, 809-817.	4.2	51
124	Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α -2b and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 177-183.	1.6	14
125	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 937-948.	3.7	209
126	The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. <i>BMC Cancer</i> , 2011, 11, 405.	2.6	48

#	ARTICLE	IF	CITATIONS
127	The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. <i>Drug Discovery Today</i> , 2011, 16, 219-228.	6.4	65
128	Truncated HER2: implications for HER2-targeted therapeutics. <i>Drug Discovery Today</i> , 2011, 16, 810-816.	6.4	23
129	Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. <i>Investigational New Drugs</i> , 2011, 29, 752-759.	2.6	41
130	Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. <i>Angiogenesis</i> , 2011, 14, 457-466.	7.2	37
131	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. <i>Molecular Cancer</i> , 2011, 10, 126.	19.2	170
132	Identification of Î²2â€m microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. <i>Proteomics - Clinical Applications</i> , 2011, 5, 422-431.	1.6	31
133	Standardization of Models and Methods Used to Assess Nanoparticles in Cardiovascular Applications. <i>Small</i> , 2011, 7, 705-717.	10.0	26
134	Identification of cell surface-specific markers to target human nucleus pulposus cells: Expression of carbonic anhydrase XII varies with age and degeneration. <i>Arthritis and Rheumatism</i> , 2011, 63, 3876-3886.	6.7	68
135	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. <i>Modern Pathology</i> , 2011, 24, 708-719.	5.5	31
136	An Intact Canonical NF-Î³B Pathway Is Required for Inflammatory Gene Expression in Response to Hypoxia. <i>Journal of Immunology</i> , 2011, 186, 1091-1096.	0.8	134
137	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6083-6096.	7.0	330
138	The Hydroxylase Inhibitor Dimethylallyl Glycine Attenuates Endotoxic Shock Via Alternative Activation of Macrophages and IL-10 Production by B1 Cells. <i>Shock</i> , 2011, 36, 295-302.	2.1	90
139	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. <i>Cancer Discovery</i> , 2011, 1, 54-67.	9.4	1,486
140	Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma. <i>British Journal of Cancer</i> , 2011, 105, 565-574.	6.4	21
141	The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. <i>Biochemical Society Transactions</i> , 2011, 39, 663-668.	3.4	32
142	Differential Proteomics Incorporating iTRAQ Labeling and Multi-dimensional Separations. <i>Methods in Molecular Biology</i> , 2011, 691, 369-383.	0.9	3
143	Tissue Microarrays and Digital Image Analysis. <i>Methods in Molecular Biology</i> , 2011, 691, 97-112.	0.9	8
144	Fibulins. , 2011, , 1403-1406.		0

#	ARTICLE	IF	CITATIONS
145	Surface-induced cell signaling events control actin rearrangements and motility. Journal of Biomedical Materials Research - Part A, 2010, 93A, 493-504.	4.0	16
146	SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Research, 2010, 20, 468-478.	1.2	35
147	The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility. Biomaterials, 2010, 31, 8188-8197.	11.4	149
148	Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer, 2010, 10, 125.	2.6	39
149	Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer, 2010, 10, 639.	2.6	38
150	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discovery Today, 2010, 15, 102-114.	6.4	45
151	Examination of cell-host biomaterial interactions via high-throughput technologies: A re-appraisal. Biomaterials, 2010, 31, 6667-6674.	11.4	25
152	Focus on Cancer Proteomics: From Discovery towards Validation. Proteomics - Clinical Applications, 2010, 4, 577-578.	1.6	0
153	Use of SELDI MS to discover and identify potential biomarkers of toxicity in InnoMed PredTox: A multi-site, multi-compound study. Proteomics, 2010, 10, 1592-1608.	2.2	16
154	Bioluminescent imaging: a critical tool in pre-clinical oncology research. Journal of Pathology, 2010, 220, 317-327.	4.5	139
155	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nature Reviews Cancer, 2010, 10, 605-617.	28.4	181
156	Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Research, 2010, 20, 392-400.	1.2	44
157	Performance of Novel Kidney Biomarkers in Preclinical Toxicity Studies. Toxicological Sciences, 2010, 116, 8-22.	3.1	101
158	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. Cancer Research, 2010, 70, 7776-7787.	0.9	25
159	PKC η regulates cell polarisation and proliferation restriction during mammary acinus formation. Journal of Cell Science, 2010, 123, 3316-3328.	2.0	31
160	Prioritization of Candidate Protein Biomarkers from an <i>In Vitro</i> Model System of Breast Tumor Progression Toward Clinical Verification. Journal of Proteome Research, 2010, 9, 1450-1459.	3.7	7
161	Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicology Letters, 2010, 196, 1-11.	0.8	33
162	Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. Pigment Cell and Melanoma Research, 2010, 23, 542-553.	3.3	20

#	ARTICLE	IF	CITATIONS
163	Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro. <i>Breast Cancer Research</i> , 2010, 12, R59.	5.0	24
164	A Machine Learning System for Identifying Hypertrophy in Histopathology Images. <i>Lecture Notes in Computer Science</i> , 2010, , 72-81.	1.3	0
165	PKC ζ regulates cell polarisation and proliferation restriction during mammary acinus formation. <i>Development (Cambridge)</i> , 2010, 137, e2007-e2007.	2.5	0
166	Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. <i>Melanoma Research</i> , 2010, 20, 392-400.	1.2	35
167	High-Throughput Proteomics Detection of Novel Splice Isoforms in Human Platelets. <i>PLoS ONE</i> , 2009, 4, e5001.	2.5	38
168	Vascular-targeted photodynamic therapy with BF ₂ -chelated Tetraaryl-Azadipyromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. <i>British Journal of Cancer</i> , 2009, 101, 1565-1573.	6.4	86
169	Omic profiling for drug safety assessment: current trends and public-private partnerships. <i>Drug Discovery Today</i> , 2009, 14, 337-342.	6.4	24
170	High sensitivity cytokine detection in acute coronary syndrome reveals up-regulation of Interferon Gamma and Interleukin-10 post Myocardial Infarction. <i>Clinical Immunology</i> , 2009, 133, 251-256.	3.2	16
171	Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. <i>International Journal of Cancer</i> , 2009, 124, 2088-2097.	5.1	128
172	JAM-1A expression positively correlates with poor prognosis in breast cancer patients. <i>International Journal of Cancer</i> , 2009, 125, 1343-1351.	5.1	115
173	Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. <i>Photochemistry and Photobiology</i> , 2009, 85, 1053-1074.	2.5	1,029
174	Identification and functional validation of therapeutic targets for malignant melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 194-214.	4.4	10
175	Selective Expression of Syntaxin-7 Protein in Benign Melanocytes and Malignant Melanoma. <i>Journal of Proteome Research</i> , 2009, 8, 1639-1646.	3.7	22
176	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 1510-1517.	2.8	79
177	Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1338-1348.	1.6	8
178	Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: An initial report from the PredTox group. <i>Experimental and Toxicologic Pathology</i> , 2008, 60, 235-245.	2.1	37
179	Applications of SELDI-MS technology in oncology. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1535-1547.	3.6	50
180	Automated image analysis in histopathology: a valuable tool in medical diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 707-725.	3.1	104

#	ARTICLE	IF	CITATIONS
181	Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R89.	5.0	113
182	Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'. <i>Breast Cancer Research</i> , 2008, 10, 102.	5.0	17
183	A microRNA DNA methylation signature for human cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13556-13561.	7.1	990
184	Selected highlights of the Third Annual Biomarkers Congress: from discovery to validation in the drug development arena. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1091-1094.	1.6	1
185	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2681-2689.	7.0	83
186	Systematic Validation of Breast Cancer Biomarkers Using Tissue Microarrays: From Construction to Image Analysis. , 2008, , 235-250.		0
187	Breast cancer proteomics: clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 209-219.	3.1	8
188	Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy. <i>Annals of Surgery</i> , 2007, 245, 259-266.	4.2	65
189	Survivin: A promising tumor biomarker. <i>Cancer Letters</i> , 2007, 249, 49-60.	7.2	229
190	Use of proteomics for the discovery of early markers of drug toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 689-704.	3.3	23
191	CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 1434-1443.	5.1	98
192	Formalin-fixed paraffin-embedded clinical tissues show spurious copy number changes in array-CGH profiles. <i>Clinical Genetics</i> , 2007, 72, 441-447.	2.0	43
193	Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 3159-3184.	5.4	86
194	Real-time quantitative reverse transcriptase-polymerase chain reaction analysis of melanoma progression-associated genes. <i>Anticancer Research</i> , 2007, 27, 1301-7.	1.1	0
195	DNA microarray-based transcriptomic profiling of an isogenic cell culture model of breast tumour cell invasion. <i>Anticancer Research</i> , 2007, 27, 1353-9.	1.1	3
196	Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. <i>Cancer Genomics and Proteomics</i> , 2007, 4, 121-34.	2.0	17
197	Low pH induces co-ordinate regulation of gene expression in oesophageal cells. <i>Carcinogenesis</i> , 2006, 27, 319-327.	2.8	46
198	Novel Method to Prepare Morphologically Rich Polymeric Surfaces for Biomedical Applications via Phase Separation and Arrest of Microgel Particles. <i>Journal of Physical Chemistry B</i> , 2006, 110, 14581-14589.	2.6	22

#	ARTICLE	IF	CITATIONS
199	Proteomic analysis of factors released from p21-overexpressing tumour cells. <i>Proteomics</i> , 2006, 6, 3739-3753.	2.2	12
200	Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction. <i>Biomaterials</i> , 2006, 27, 3096-3108.	11.4	208
201	Molecular basis of cell-biomaterial interaction: Insights gained from transcriptomic and proteomic studies. <i>Biomaterials</i> , 2006, 27, 5871-5882.	11.4	61
202	Heteroaryl substituted titanocenes as potential anti-cancer drugs. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 1479-1486.	3.5	40
203	TGF- β 1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. <i>Vascular Pharmacology</i> , 2006, 44, 469-475.	2.1	29
204	The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line. <i>BMC Bioinformatics</i> , 2006, 7, 256.	2.6	13
205	Novel α -chitosan hydrogels as potential drug-eluting stent coatings: Controlled release of fluvastatin. <i>Journal of Biomedical Materials Research - Part A</i> , 2006, 79A, 923-933.	4.0	31
206	Functional interrogation of breast cancer: from models to drugs. <i>Expert Opinion on Drug Discovery</i> , 2006, 1, 569-584.	5.0	3
207	CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. <i>Clinical Cancer Research</i> , 2006, 12, 6421-6431.	7.0	123
208	Protein Tyrosine Phosphatases, New Targets for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2006, 6, 519-532.	1.6	55
209	A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug. <i>Polyhedron</i> , 2005, 24, 1250-1255.	2.2	40
210	A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia. <i>British Journal of Cancer</i> , 2005, 92, 1702-1710.	6.4	100
211	Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. <i>Applied Organometallic Chemistry</i> , 2005, 19, 293-300.	3.5	68
212	Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. <i>Carcinogenesis</i> , 2005, 26, 1856-1867.	2.8	108
213	Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1069-1083.	3.1	46
214	DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005, 3, 289-304.	0.3	10
215	Supramolecular Photonic Therapeutic Agents. <i>Journal of the American Chemical Society</i> , 2005, 127, 16360-16361.	13.7	323
216	Correlation of the Adhesive Properties of Cells to N-Isopropylacrylamide/N-tert-Butylacrylamide Copolymer Surfaces with Changes in Surface Structure Using Contact Angle Measurements, Molecular Simulations, and Raman Spectroscopy. <i>Chemistry of Materials</i> , 2005, 17, 3889-3898.	6.7	46

#	ARTICLE	IF	CITATIONS
217	Fibulins and cancer: friend or foe?. Trends in Molecular Medicine, 2005, 11, 336-340.	6.7	134
218	Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis, 2004, 25, 1599-1609.	2.8	61
219	Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems. , 2004, 102, 1-15.		88
220	In Vitro Demonstration of the Heavy-Atom Effect for Photodynamic Therapy. Journal of the American Chemical Society, 2004, 126, 10619-10631.	13.7	768
221	Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Journal of Organometallic Chemistry, 2004, 689, 2242-2249.	1.8	91
222	Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride. Journal of Inorganic Biochemistry, 2004, 98, 1987-1994.	3.5	54
223	Elevated expression and altered processing of fibulin-1 protein in human breast cancer. British Journal of Cancer, 2003, 88, 871-878.	6.4	68
224	Fibulins: physiological and disease perspectives. EMBO Reports, 2003, 4, 1127-1131.	4.5	288
225	Interaction of soft condensed materials with living cells: Phenotype/transcriptome correlations for the hydrophobic effect. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6331-6336.	7.1	78
226	Poly(N-isopropylacrylamide) co-polymer films as potential vehicles for delivery of an antimetabolic agent to vascular smooth muscle cells. Cardiovascular Pathology, 2003, 12, 105-110.	1.6	65
227	Synthesis of BF ₂ chelates of tetraarylazadipyrromethenes and evidence for their photodynamic therapeutic behaviour. Chemical Communications, 2002, , 1862-1863.	4.1	324
228	Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Letters, 2001, 489, 59-66.	2.8	62
229	MBP1: a novel mutant p53-specific protein partner with oncogenic properties. Oncogene, 1999, 18, 3608-3616.	5.9	56
230	hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 1997, 15, 45-52.	5.9	226
231	Structural basis of p21H-ras molecular switch inhibition by a neutralizing antibody. Journal of Molecular Graphics, 1996, 14, 42-50.	1.1	1